 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes MINOCYCLINE increase or decrease the risk[0m
[34mof gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"MINOCYCLINE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mMINOCYCLINE[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mMINOCYCLINE[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Provide information about the drug Minocycline."[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"Minocycline"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: MINOCYCLINE: indications_and_usage: [0m[1;31m1[0m[31m INDICATIONS AND USAGE Minocycline hydrochloride extended-release tablets is tetracycline-class drug indicated to treat only inflammatory lesions of [0m
[31mnon-nodular moderate to severe acne vulgaris in patients [0m[1;31m12[0m[31m years of age and older. [0m[1;31m([0m[31m [0m[1;31m1[0m[31m [0m[1;31m)[0m[31m [0m[1;31m1.1[0m[31m Indication Minocycline hydrochloride extended-release tablets are indicated to treat only inflammatory [0m
[31mlesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;31m12[0m[31m years of age and older. [0m[1;31m1.2[0m[31m Limitations of Use Minocycline hydrochloride extended-release tablets did not demonstrate any effect [0m
[31mon non-inflammatory acne lesions. Safety of minocycline hydrochloride extended-release tablets has not been established beyond [0m[1;31m12[0m[31m weeks of use. This formulation of minocycline has not been evaluated [0m
[31min the treatment of infections [0m[31m. MINOCYCLINE: indications_and_usage: To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, [0m
[31mminocycline hydrochloride extended-release tablets should be used only as indicated [0m[31m.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: description: [0m[1;31m11[0m[31m DESCRIPTION Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [0m
[1;31m[[0m[31m4S-[0m[1;31m([0m[31m4Î±,4aÎ±,5aÎ±,12aÎ±[0m[1;31m)[0m[1;31m][0m[1;31m-4[0m[31m,[0m[1;31m7[0m[31m-[0m[1;31mBis[0m[1;31m([0m[31mdimethylamino[0m[1;31m)[0m[1;31m-1[0m[31m,[0m[1;31m4[0m[31m,4a,[0m[1;31m5[0m[31m,5a,[0m[1;31m6[0m[31m,[0m[1;31m11[0m[31m,12a-octahydro-[0m[1;31m3[0m[31m,[0m[1;31m10[0m[31m,[0m[1;31m12[0m[31m,12a-tetrahydroxy-[0m[1;31m1[0m[31m,[0m[1;31m11[0m[31m-dioxo-[0m[1;31m2[0m[31m-naphthacenecarboxamide mono hydrochloride. The structural formula is represented [0m
[31mbelow: Minocycline hydrochloride extended-release tablets for oral administration contain minocycline hydrochloride, USP equivalent to [0m[1;31m45[0m[31m mg, [0m[1;31m90[0m[31m mg, or [0m[1;31m135[0m[31m mg of minocycline. MINOCYCLINE: description:[0m
[31mIn addition, [0m[1;31m45[0m[31m mg, [0m[1;31m90[0m[31m mg, and [0m[1;31m135[0m[31m mg tablets contain the following inactive ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, and magnesium stearate. The [0m[1;31m45[0m[31m mg [0m
[31mextended-release tablets also contain opadry grey, which contains: titanium dioxide, triacetin, iron oxide black, and iron oxide yellow. The [0m[1;31m90[0m[31m mg extended-release tablets also contain opadry orange, [0m
[31mwhich contains: titanium dioxide, triacetin, iron oxide yellow, FD&C yellow # [0m[1;31m6[0m[31m, and iron oxide red. The [0m[1;31m135[0m[31m mg extended-release tablets also contain opadry yellow, which contains: titanium dioxide, [0m
[31mtriacetin and iron oxide yellow. MINOCYCLINE: description: structure formula         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION [0m[1;31m[[0m[31mSee FDA-approved patient labeling [0m[1;31m([0m[31mPatient Information[0m[1;31m)[0m[1;31m][0m[31m Patients taking minocycline hydrochloride extended-release [0m
[31mtablets should receive the following information and instructions: â€¢ Minocycline hydrochloride extended-release tablets should not be used by pregnant women or women attempting to conceive a child [0m[31m. â€¢[0m
[31mIt is recommended that minocycline hydrochloride extended-release tablets not be used by men who are attempting to father a child [0m[31m. â€¢ Patients should be advised that pseudomembranous colitis can occur[0m
[31mwith minocycline therapy. If patients develop watery or bloody stools, they should seek medical attention. â€¢ Patients should be counseled about the possibility of hepatotoxicity. MINOCYCLINE: [0m
[31minformation_for_patients: Patients should seek medical advice if they experience symptoms which can include loss of appetite, tiredness, diarrhea, skin turning yellow, bleeding easily, confusion, and [0m
[31msleepiness. â€¢ Patients who experience central nervous system symptoms [0m[31m should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. Patients should seek [0m
[31mmedical help for persistent headaches or blurred vision. â€¢ Concurrent use of tetracycline may render oral contraceptives less effective [0m[31m. â€¢ Autoimmune syndromes, including drug-induced lupus-like [0m
[31msyndrome, autoimmune hepatitis, vasculitis and serum sickness have been observed with tetracycline-class drugs, including minocycline. Symptoms may be manifested by arthralgia, fever, rash and [0m
[31mmalaise. Patients who experience such symptoms should be cautioned to stop the drug immediately and seek medical help. MINOCYCLINE: information_for_patients: â€¢ Patients should be counseled about [0m
[31mdiscoloration of skin, scars, teeth or gums that can arise from minocycline therapy. â€¢ Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking [0m
[31mtetracyclines, including minocycline. Patients should minimize or avoid exposure to natural or artificial sunlight [0m[1;31m([0m[31mtanning beds or UVA/B treatment[0m[1;31m)[0m[31m while using minocycline. If patients need to be [0m
[31moutdoors while using minocycline, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. Treatment should be [0m
[31mdiscontinued at the first evidence of skin erythema. â€¢ Minocycline hydrochloride extended-release tablets should be taken exactly as directed. Skipping doses or not completing the full course of [0m
[31mtherapy may decrease the effectiveness of the current treatment course and increase the likelihood that bacteria will develop resistance and will not be treatable by other antibacterial drugs in the [0m
[31mfuture.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: â€¢ Stop taking minocycline hydrochloride extended-release tablets and get medical help right away if you have any of these symptoms: âˆ˜ skin rash, [0m
[31mhives, sores in your mouth, or your skin blisters and peels âˆ˜ swelling of your face, eyes, lips, tongue, or throat âˆ˜ trouble swallowing or breathing âˆ˜ blood in your urine âˆ˜ fever, yellowing of the [0m
[31mskin or the whites of your eyes, dark colored urine âˆ˜ pain on the right side of the stomach area [0m[1;31m([0m[31mabdominal pain[0m[1;31m)[0m[31m âˆ˜ chest pain or abnormal heartbeats âˆ˜ swelling in your legs, ankles and feet âˆ˜ [0m
[31mdarkening of your nails, skin, eyes, scars, teeth, and gums. The most common side effects of minocycline hydrochloride extended-release tablets include: â€¢ headache â€¢ tiredness â€¢ dizziness or spinning [0m
[31mfeeling â€¢ itching Call your doctor if you have a side effect that bothers you or that does not go away. MINOCYCLINE: spl_patient_package_insert: Your doctor may do tests to check you for side effects [0m
[31mduring treatment with minocycline hydrochloride extended-release tablets. These are not all the side effects with minocycline hydrochloride extended-release tablets. Ask your doctor or pharmacist for [0m
[31mmore information. Call your doctor for medical advice about side effects. You may report side effects to Sandoz Inc. at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. How should I store minocycline [0m
[31mhydrochloride extended-release tablets? â€¢ Store minocycline hydrochloride extended-release tablets at 20Âº to 25ÂºC [0m[1;31m([0m[31m68Âº to 77ÂºF[0m[1;31m)[0m[31m [0m[31m. â€¢ Keep minocycline hydrochloride extended-release tablets in the [0m
[31mcontainer that it comes in and keep container tightly closed. â€¢ Keep minocycline hydrochloride extended-release tablets dry. MINOCYCLINE: spl_patient_package_insert: Keep minocycline hydrochloride [0m
[31mextended-release tablets and all medicines out of the reach of children. General Information about minocycline hydrochloride extended-release tablets Medicines are sometimes prescribed for purposes [0m
[31mother than those listed in the Patient Information Leaflet. Do not use minocycline hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give minocycline [0m
[31mhydrochloride extended-release tablets to other people, even if they have the same symptoms you have. It may harm them. This Patient Information leaflet summarizes the most important information about[0m
[31mminocycline hydrochloride extended-release tablets. If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about minocycline hydrochloride [0m
[31mextended-release tablets that is written for health professionals. For more information, call Sandoz Inc. MINOCYCLINE: spl_patient_package_insert: at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-[0m[1;31m525[0m[31m-[0m[1;31m8747[0m[31m What are the ingredients in [0m
[31mminocycline hydrochloride extended-release tablets? Active Ingredient: Minocycline Hydrochloride, USP Inactive Ingredients: colloidal silicon dioxide, hypromellose, lactose monohydrate, and magnesium [0m
[31mstearate. The [0m[1;31m45[0m[31m mg extended-release tablets also contain opadry grey, which contains: titanium dioxide, triacetin, iron oxide black, and iron oxide yellow. The [0m[1;31m90[0m[31m mg extended-release tablets also [0m
[31mcontain opadry orange, which contains: titanium dioxide, triacetin, iron oxide yellow, FD&C yellow #[0m[1;31m6[0m[31m, and iron oxide red. The [0m[1;31m135[0m[31m mg extended-release tablets also contain opadry yellow, which [0m
[31mcontains: titanium dioxide, triacetin and iron oxide yellow. MINOCYCLINE: spl_patient_package_insert: Manufactured by: USV Private Limited, OIDC, Mahatma Gandhi Udyog Nagar, Dabhel, Daman [0m[1;31m396210[0m[31m, [0m
[31mIndia for Sandoz Inc., Princeton, NJ [0m[1;31m08540[0m[31m Rev.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics The pharmacodynamics of minocycline hydrochloride extended-release tablets for the treatment of acne are unknown.         [0m
[31mSOURCE:MINOCYCLINE label[0m


[31mCONTENT: MINOCYCLINE: spl_patient_package_insert: Patient Information Minocycline Hydrochloride Extended-Release Tablets Rx only Read this patient information leaflet that comes with minocycline [0m
[31mhydrochloride extended-release tablets before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about [0m
[31myour condition or treatment. What are minocycline hydrochloride extended-release tablets? Minocycline hydrochloride is tetracycline-class drug. Minocycline hydrochloride extended-release tablets are [0m
[31mprescription medicine used to treat pimples and red bumps [0m[1;31m([0m[31mnon-nodular inflammatory lesions[0m[1;31m)[0m[31m that happen with moderate to severe acne vulgaris in people [0m[1;31m12[0m[31m years and older. Minocycline hydrochloride [0m
[31mextended-release tablets are not effective for acne that is not red-looking [0m[1;31m([0m[31mthis means acne that is not inflammatory[0m[1;31m)[0m[31m. MINOCYCLINE: spl_patient_package_insert: It is not known if minocycline [0m
[31mhydrochloride extended-release tablets are: â€¢ safe for use longer than [0m[1;31m12[0m[31m weeks. â€¢ safe and effective for the treatment of infections. â€¢ safe and effective in children under the age of [0m[1;31m12[0m[31m years. Who [0m
[31mshould not take minocycline hydrochloride extended-release tablets? Do not take minocycline hydrochloride extended-release tablets if you are allergic to tetracycline-class drugs. Ask your doctor or [0m
[31mpharmacist for a list of these medicines if you are not sure. What should I tell my doctor before taking minocycline hydrochloride extended-release tablets? Before you take minocycline hydrochloride [0m
[31mextended-release tablets, tell your doctor if you: â€¢ have kidney problems. Your doctor may prescribe a lower dose of medicine for you. â€¢ have liver problems. â€¢ have diarrhea or watery stools. â€¢ have [0m
[31mvision problems. â€¢ plan to have surgery with general anesthesia. â€¢ have any other medical conditions. MINOCYCLINE: spl_patient_package_insert: â€¢ are a male, and you and your female partner are trying [0m
[31mto conceive a baby. You should not take minocycline hydrochloride extended-release tablets â€¢ are pregnant or plan to become pregnant. Minocycline hydrochloride extended-release tablets may harm your [0m
[31munborn baby. Taking minocycline hydrochloride extended-release tablets while you are pregnant may cause serious side effects on the growth of bone and teeth of your baby. Talk to your doctor before [0m
[31mtaking minocycline hydrochloride extended-release tablets if you plan to become pregnant, or if you are already taking minocycline hydrochloride extended-release tablets and plan to become pregnant. [0m
[31mStop taking minocycline hydrochloride extended-release tablets and call your doctor right away if you become pregnant while taking minocycline hydrochloride extended-release tablets. â€¢ are [0m
[31mbreastfeeding or plan to breastfeed. Minocycline hydrochloride passes into your milk and may harm your baby.         [0m
[31mSOURCE:MINOCYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Minocycline hydrochloride extended-release tablets are a tetracycline-class drug indicated for the treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in [0m
[32mpatients [0m[1;32m12[0m[32m years of age and older. The safety of minocycline hydrochloride extended-release tablets has not been established beyond [0m[1;32m12[0m[32m weeks of use, and it has not been evaluated in the treatment of [0m
[32minfections. It is not effective for non-inflammatory acne lesions. The drug should not be used by pregnant women, women attempting to conceive, or men who are attempting to father a child. Patients [0m
[32mshould be aware of potential side effects such as pseudomembranous colitis, hepatotoxicity, central nervous system symptoms, autoimmune syndromes, discoloration of skin, scars, teeth, or gums, and [0m
[32mphotosensitivity. Minocycline hydrochloride extended-release tablets come in doses equivalent to [0m[1;32m45[0m[32m mg, [0m[1;32m90[0m[32m mg, or [0m[1;32m135[0m[32m mg of minocycline and contain various inactive ingredients. The pharmacodynamics [0m
[32mof minocycline for the treatment of acne are unknown.[0m

[32mSOURCE: Minocycline label[0m
[32mEXTRACT_START_END: [0m[1;32m1[0m[32m INDICATIONS AND USAGE Minocycline hydrochloride[0m[32m...[0m[32mtreatment of infections [0m[32m.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Minocycline hydrochloride [0m
[34mextended-release tablets are a tetracycline-class drug indicated for the treatment of only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;34m12[0m[34m years of age and older. [0m
[34mThe safety of minocycline hydrochloride extended-release tablets has not been established beyond [0m[1;34m12[0m[34m weeks of use, and it has not been evaluated in the treatment of infections. It is not effective for [0m
[34mnon-inflammatory acne lesions. The drug should not be used by pregnant women, women attempting to conceive, or men who are attempting to father a child. Patients should be aware of potential side [0m
[34meffects such as pseudomembranous colitis, hepatotoxicity, central nervous system symptoms, autoimmune syndromes, discoloration of skin, scars, teeth, or gums, and photosensitivity. Minocycline [0m
[34mhydrochloride extended-release tablets come in doses equivalent to [0m[1;34m45[0m[34m mg, [0m[1;34m90[0m[34m mg, or [0m[1;34m135[0m[34m mg of minocycline and contain various inactive ingredients. The pharmacodynamics of minocycline for the [0m
[34mtreatment of acne are unknown.[0m

[34mSOURCE: Minocycline label[0m
[34mEXTRACT_START_END: [0m[1;34m1[0m[34m INDICATIONS AND USAGE Minocycline hydrochloride[0m[34m...[0m[34mtreatment of infections [0m[34m.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for minocycline hydrochloride [0m
[32mextended-release tablets, as provided by FDAHandler, indicates that the drug is used for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients [0m[1;32m12[0m[32m years of [0m
[32mage and older. The label mentions several potential side effects, including pseudomembranous colitis, hepatotoxicity, central nervous system symptoms, autoimmune syndromes, discoloration of skin, [0m
[32mscars, teeth, or gums, and photosensitivity. However, there is no specific mention of gastrointestinal ulcer or its association with hospitalization as a side effect of minocycline in the provided [0m
[32mexcerpt.[0m

[32mGiven the information provided, we cannot determine whether minocycline increases or decreases the risk of gastrointestinal ulcer hospitalization based on the FDA label data alone. Therefore, the [0m
[32manswer to the question is DO-NOT-KNOW, because the FDA label data does not specify the answer.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does MINOCYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I requested information from FDAHandler about MINOCYCLINE."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided the label information for minocycline, which mentions several potential side effects but does not specifically mention gastrointestinal ulcers or their association with [0m
[32mhospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does MINOCYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I requested information from FDAHandler about MINOCYCLINE."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided the label information for minocycline, which mentions several potential side effects but does not specifically mention gastrointestinal ulcers or their association with [0m
[34mhospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does MINOCYCLINE increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I requested information from FDAHandler about MINOCYCLINE.[0m
[1;31m2[0m[31m. FDAHandler provided the label information for minocycline, which mentions several potential side effects but does not specifically mention gastrointestinal ulcers or their association with [0m
[31mhospitalization.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-MINOCYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe question was whether MINOCYCLINE increases or decreases the risk of gastrointestinal ulcer hospitalization. The information provided by FDAHandler from the minocycline label did not mention [0m
[32mgastrointestinal ulcers or their association with hospitalization as a side effect. Therefore, based on the FDA label data, we cannot determine the effect of minocycline on the risk of [0m
[32mgastrointestinal ulcer hospitalization.[0m
